INVESTIGATIONAL NEW DRUGS

Scope & Guideline

Driving Discoveries in Oncology and Pharmacology

Introduction

Welcome to your portal for understanding INVESTIGATIONAL NEW DRUGS, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0167-6997
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1983 to 2024
AbbreviationINVEST NEW DRUG / Invest. New Drugs
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal 'Investigational New Drugs' primarily focuses on the research and development of novel therapeutic agents aimed at treating various types of cancers and other serious diseases. It emphasizes the importance of clinical trials and translational research in the field of oncology, providing insights into the efficacy, safety, and mechanisms of action of new drugs. The journal encompasses a wide range of topics related to drug discovery, pharmacokinetics, and patient outcomes.
  1. Clinical Trials and Pharmacotherapy:
    The journal publishes studies related to various phases of clinical trials for new cancer therapies, highlighting their efficacy, safety, and potential side effects.
  2. Mechanisms of Action of Anticancer Drugs:
    Research articles delve into the biological mechanisms underlying the effects of new drugs, including their interactions at the molecular level and their influence on cellular pathways.
  3. Emerging Therapeutic Strategies:
    Focus on innovative therapeutic approaches, such as combination therapies, immunotherapies, and targeted therapies that aim to improve treatment outcomes for cancer patients.
  4. Real-World Evidence and Outcomes:
    Articles often include analyses of real-world data, assessing the effectiveness and safety of treatments in diverse patient populations outside of clinical trials.
  5. Pharmacokinetics and Drug Interactions:
    The journal emphasizes studies that explore the pharmacokinetic profiles of drugs, including absorption, distribution, metabolism, and excretion, as well as potential drug-drug interactions.
The landscape of cancer research is rapidly evolving, and 'Investigational New Drugs' reflects these changes through emerging trends and themes that are gaining traction in recent publications. These trends highlight the journal's commitment to advancing the field of oncology through innovative research and clinical practices.
  1. Immunotherapy and Checkpoint Inhibitors:
    A significant increase in studies focusing on immunotherapeutic agents, particularly immune checkpoint inhibitors, indicates a growing interest in harnessing the immune system to fight cancer.
  2. Targeted Therapies and Precision Medicine:
    Recent publications emphasize the development of targeted therapies that are tailored to specific genetic mutations in tumors, reflecting a trend towards precision medicine in oncology.
  3. Combination Therapy Approaches:
    There is a growing body of research focused on the efficacy of combination therapies that integrate various treatment modalities, aiming to enhance treatment outcomes and overcome resistance.
  4. Patient-Centered Outcomes and Quality of Life:
    Emerging themes include studies that assess the impact of cancer treatments on patient quality of life and other patient-centered outcomes, showcasing a holistic approach to cancer care.
  5. Real-World Evidence Studies:
    The journal is increasingly publishing studies that utilize real-world data to evaluate treatment effectiveness and safety, bridging the gap between clinical trials and everyday clinical practice.

Declining or Waning

While 'Investigational New Drugs' continues to cover a broad spectrum of topics in drug development and oncology, certain areas of focus appear to be waning in prominence based on recent publication trends. These declining themes may reflect shifts in research priorities or advancements in understanding specific aspects of cancer treatment.
  1. Traditional Chemotherapy Studies:
    There is a noticeable decrease in publications focused solely on traditional chemotherapy regimens, as the field increasingly emphasizes targeted therapies and immunotherapies.
  2. Monotherapy Approaches:
    Research centered on single-agent therapies is declining, with a shift towards combination therapies that harness multiple mechanisms to combat cancer.
  3. Basic Pharmacology Studies:
    The journal has seen fewer articles dedicated solely to basic pharmacological studies of established drugs, as the focus has shifted towards novel agents and innovative treatment strategies.
  4. Focus on Rare Cancers:
    There appears to be a reduction in studies specifically targeting rare cancers, possibly due to a greater emphasis on more prevalent cancer types that attract larger patient populations for clinical trials.

Similar Journals

Drug Discoveries and Therapeutics

Bridging research and practice in drug therapeutics.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

DRUGS IN R&D

Catalyzing discoveries in drug research and development.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

ANTIVIRAL THERAPY

Leading the charge in antiviral therapy advancements.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Connecting Ideas, Enhancing Therapies
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Enhancing knowledge for a healthier heart.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Transforming cancer care with cutting-edge pharmacological insights.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Iranian Journal of Pharmaceutical Research

Connecting scholars to elevate the standards of drug research.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

ANNALS OF PHARMACOTHERAPY

Fostering Excellence in Medical Research and Education
Publisher: SAGE PUBLICATIONS INCISSN: 1060-0280Frequency: 12 issues/year

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Advancing pharmacological knowledge for better patient care.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Translational and Clinical Pharmacology

Empowering Pharmacological Insights for Tomorrow
Publisher: KSCPTISSN: 2289-0882Frequency:

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.